1. |
Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019. CA Cancer J Clin, 2019, 69(1): 7-34.
|
2. |
Chen W, Zheng R, Baade PD, et al. Cancer statistics in China, 2015. CA Cancer J Clin, 2016, 66(2): 115-132.
|
3. |
Zhang ZM, Lai EC, Zhang C, et al. The strategies for treating primary hepatocellular carcinoma with portal vein tumor thrombus. Int J Surg, 2015, 20: 8-16.
|
4. |
European Association for the Study of the Liver. EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma. J Hepatol, 2018, 69(1): 182-236.
|
5. |
Zhang XP, Wang K, Li N, et al. Survival benefit of hepatic resection versus transarterial chemoembolization for hepatocellular carcinoma with portal vein tumor thrombus: a systematic review and meta-analysis. BMC Cancer, 2017, 17(1): 902.
|
6. |
Leng JJ, Xu YZ, Dong JH. Efficacy of transarterial chemoembolization for hepatocellular carcinoma with portal vein thrombosis: a meta-analysis. ANZ J Surg, 2016, 86(10): 816-820.
|
7. |
程树群, 吴孟超, 陈汉, 等. 肝癌门静脉癌栓分型的影像学意义. 中华普通外科杂志, 2004, 19(4): 200-201.
|
8. |
Chen SQ, WU MC, Chen H, et al. Tumor thrombus types influence the prognosis of hepatocellular carcinoma with the tumor thrombi in the portal vein. Hepatogastroenterology, 2007, 54(74): 499-502.
|
9. |
Ikai I, Yamamoto Y, Yamamoto N, et al. Results of hepatic resection for hepatocellular carcinoma invading major portal and/or hepatic veins. Surg Oncol Clin N Am, 2003, 12(1): 65-75.
|
10. |
Kudo M, Kitano M, Sakurai T, et al. General rules for the clinical and pathological study of primary liver cancer, nationwide follow-up survey and clinical practice guidelines: The outstanding achievements of the Liver Cancer Study Group of Japan. Dig Dis, 2015, 33(6): 765-770.
|
11. |
Shi J, Lai EC, Li N, et al. Surgical treatment of hepatocellular carcinoma with portal vein tumor thrombus. Ann Surg Oncol, 2010, 17(8): 2073-2080.
|
12. |
Shi J, Lai EC, Li N, et al. A new classification for hepatocellular carcinoma with portal vein tumor thrombus. J Hepatobiliary Pancreat Sci, 2011, 18(1): 74-80.
|
13. |
Luo J, Guo RP, Lai EC, et al. Transarterial chemoembolization for unresectable hepatocellular carcinoma with portal vein tumor thrombosis: a prospective comparative study. Ann Surg Oncol, 2011, 18(2): 413-420.
|
14. |
Lee HS, Kim JS, Choi IJ, et al. The safety and efficacy of transcatheter arterial chemoembolization in the treatment of patients with hepatocellular carcinoma and main portal vein obstruction. A prospective controlled study. Cancer, 1997, 79(11): 2087-2094.
|
15. |
Niu ZJ, Ma YL, Kang P, et al. Transarterial chemoembolization compared with conservative treatment for advanced hepatocellular carcinoma with portal vein tumor thrombus: using a new classification. Med Oncol, 2012, 29(4): 2992-2997.
|
16. |
Chung GE, Lee JH, Kim HY, et al. Transarterial chemoembolization can be safely performed in patients with hepatocellular carcinoma invading the main portal vein and may improve the overall survival. Radiology, 2011, 258(2): 627-634.
|
17. |
Kim KM, Kim JH, Park IS, et al. Reappraisal of repeated transarterial chemoembolization in the treatment of hepatocellular carcinoma with portal vein invasion. J Gastroenterol Hepatol, 2009, 24(5): 806-814.
|
18. |
Peng ZW, Guo RP, Zhang YJ, et al. Hepatic resection versus transcatheter arterial chemoembolization for the treatment of hepatocellular carcinoma with portal vein tumor thrombus. Cancer, 2012, 118(19): 4725-4736.
|
19. |
Zheng N, Wei X, Zhang D, et al. Hepatic resection or transarterial chemoembolization for hepatocellular carcinoma with portal vein tumor thrombus. Medicine (Baltimore), 2016, 95(26): e3959.
|
20. |
Zhou Q, Wang Y, Zhou X, et al. Prognostic analysis for treatment modalities in hepatocellular carcinomas with portal vein tumor thrombi. Asian Pac J Cancer Prev, 2011, 12(11): 2847-2850.
|
21. |
Xue TC, Xie XY, Zhang L, et al. Transarterial chemoembolization for hepatocellular carcinoma with portal vein tumor thrombus: a meta-analysis. BMC Gastroenterol, 2013, 13: 60.
|
22. |
马良, 叶甲舟, 向邦德, 等. 不同治疗方案对直径小于 10 cm 肝细胞癌合并门静脉癌栓患者生存率的影响. 中华肝胆外科杂志, 2013, 19(3): 165-170.
|
23. |
黎洪浩, 区庆嘉, 陈积圣, 等. 肝癌根治性切除术后联合肝动脉化疗栓塞和门静脉化疗对预防复发的价值. 中华肿瘤杂志, 2000, 22(1): 61-77.
|
24. |
Peng BG, He Q, Li JP, et al. Adjuvant transcatheter arterial chemoembolization improves efficacy of hepatectomy for patients with hepatocellular carcinoma and portal vein tumor thrombus. Am J Surg, 2009, 198(3): 313-318.
|
25. |
Zhong C, Guo RP, Li JQ, et al. A randomized controlled trial of hepatectomy with adjuvant transcatheter arterial chemoembolization versus hepatectomy alone for stage Ⅲ A hepatocellular carcinoma. J Cancer Res Clin Oncol, 2009, 135(10): 1437-1445.
|
26. |
Zhang YF, Guo RP, Zou RH, et al. Efficacy and safety of preoperative chemoembolization for resectable hepatocellular carcinoma with portal vein invasion: a prospective comparative study. Eur Radiol, 2016, 26(7): 2078-2088.
|
27. |
Li JQ, Zhang YQ, Zhang WZ, et al. Randomized study of chemoembolization as an adjuvant therapy for primary liver carcinoma after hepatectomy. J Cancer Res Clin Oncol, 1995, 121(6): 364-366.
|
28. |
Shi M, Zhang CQ, Zhang YQ, et al. Micrometastases of solitary hepatocellular carcinoma and appropriate resection margin. World J Surg, 2004, 28(4): 376-381.
|
29. |
Sun JJ, Wang K, Zhang CZ, et al. Postoperative adjuvant transcatheter arterial chemoembolization after r0 hepatectomy improves outcomes of patients who have hepatocellular carcinoma with microvascular invasion. Ann Surg Oncol, 2016, 23(4): 1344-1351.
|
30. |
Li XL, Guo WX, Hong XD, et al. Efficacy of the treatment of transarterial chemoembolization combined with radiotherapy for hepatocellular carcinoma with portal vein tumor thrombus: A propensity score analysis. Hepatol Res, 2016, 46(11): 1088-1098.
|
31. |
Rim CH, Yang DS, Park YJ, et al. Effectiveness of high-dose three-dimensional conformal radiotherapy in hepatocellular carcinoma with portal vein thrombosis. Jpn J Clin Oncol, 2012, 42(8): 721-729.
|
32. |
Wahl DR, Stenmark MH, Tao Y, et al. Outcomes after stereotactic body radiotherapy or radiofrequency ablation for hepatocellular carcinoma. J Clin Oncol, 2016, 34(5): 452-459.
|
33. |
广东省抗癌协会肝癌专业委员会广东省医学会肝胆胰外科学分会. 肝细胞肝癌合并门静脉癌栓多学科团队综合治疗广东专家共识(2015版). 中华消化外科杂志, 2015, 14(9): 694-701.
|
34. |
全国肝癌合并癌栓诊治研究协作组. 肝细胞癌合并门静脉癌栓多学科诊治中国专家共识(2016年版). 中华医学杂志, 2016, 96(18): 1399-1404.
|
35. |
Bruix J, Raoul JL, Sherman M, et al. Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma: subanalyses of a phase Ⅲ trial. J Hepatol, 2012, 57(4): 821-829.
|
36. |
Choi GH, Shim JH, Kim MJ, et al. Sorafenib alone versus sorafenib combined with transarterial chemoembolization for advanced-stage hepatocellular carcinoma: results of propensity score analyses. Radiology, 2013, 269(2): 603-611.
|
37. |
Zhu K, Chen J, Lai L, et al. Hepatocellular carcinoma with portal vein tumor thrombus: treatment with transarterial chemoembolization combined with sorafenib—a retrospective controlled study. Radiology, 2014, 272(1): 284-293.
|
38. |
Yang M, Yuan JQ, Bai M, et al. Transarterial chemoembolization combined with sorafenib for unresectable hepatocellular carcinoma: a systematic review and meta-analysis. Mol Biol Rep, 2014, 41(10): 6575-6582.
|
39. |
Zhang L, Hu P, Chen X, et al. Transarterial chemoembolization (TACE) plus sorafenib versus TACE for intermediate or advanced stage hepatocellular carcinoma: a meta-analysis. PLoS One, 2014, 9(6): e100305.
|